Sex hormone-induced mammary carcinogenesis in female Noble rats: Expression of TGF-β1 and its receptors, TGF-α, and EGF-R in mammary carcinogenesis

Breast Cancer Research and Treatment

Volumn 58, Issue 3, 1999, Pages 227-239

  Xie, B ^a   Tsao, S W ^a   Wong, Y C ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

EGF R; Mammary carcinogenesis; Sex hormones; TGF BRI; TGF BRII; TGF ; TGF ; TGF 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; FLUTAMIDE; SEX HORMONE; TAMOXIFEN; TESTOSTERONE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CELL INTERACTION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STROMA CELL;

EID: 0033491957     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006349532643     Document Type: Article

References (63)

1. 1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics 1997. CA Cancer J Clin 47: 5-27, 1997
2. 2. Boyle, P. (1988) Epidemiology of breast cancer. Bailliere's Clin Oncol 2: 1.
3. 3. Dickson RB, Lippman ME: Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8: 29-43, 1987
4. 4. Horwitz KB, McGuire WL: Nuclear mechanism of estrogen action. Effect of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem 253: 8185-8191, 1978
5. 5. Rochefort H, Garcia M: The estrogenic and antiestrogenic activites of androgens in female target tissues. Pharmacol Ther 23: 193-216, 1983
6. 6. Kesey JL: Breast cancer epidemiology: Summary and future directions. Epidemiol Rev 15: 256-263, 1993
7. 7. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G: Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 88: 291-296, 1996
8. 8. Bernstein L, Ross RK: Endogenous hormones and breast cancer risk. Epidemiol Rev 15: 48-65, 1993
9. 9. Sereto G, Toniolo P, Berrino F: Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Res 51: 2572-2576, 1991
10. 10. Veronesi U, Pizzocaro G: Breast cancer in women subsequent to cystic disease of the breast. Surg Gynec Obst 126: 529-532, 1968
11. 11. Secreto G, Toniolo P, Berrino F, Recchione C, Pietro SD, Fariselli G, Decarli A: Increased androgen activity and breast cancer risk in premenopausal women. Cancer Res 44: 5902-5905, 1984
12. 12. Dorgan JF, Longcope C, Stephenson Jr HE, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A: Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environ Health Perspect 105(Suppl.): 583-585, 1997
13. 13. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, van der Kwast TH: Androgen receptor expression in human tissues: An immunohistochemical study. J Histochem Cytochem 39: 927, 1991
14. 14. Janssen PJ, Brinkmann AO, Boersma WJ, van der Kwast TH: Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processed, paraffin-embedded human tissues after microwave pre-treatment. J Histochem Cytochem 42: 1169-1175, 1994
15. 15. Kimura N, Mizokami A: Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. J Histochem Cytochem 42: 126, 1994
16. 16. Wong YC, Xie B, Tsao GSW: Induction of breast cancer in Noble rats with a combination of estrogen and testosterone. In: Li JJ, Daling J, Li SA (eds) Hormonal Carcinogenesis (Vol 3), Springer-Verlag (in press), 1999
17. 17. Xie B, Tsao SW, Wong YC: Induction of high incidence of mammary tumor in female Noble Rats with a combination of 17β-oestradiol and testosterone. Carcinogenesis 20: 1069-1078, 1999
18. 18. Liao DJ, Hou X, Pantazis C, Bai S, Li SA, Li JJ: Combined treatment of estrogen and androgen is more effective than estrogen alone in induction of mammary adenocarcinoma in the male Noble rat ('abstract'). Am Asso Cancer Res 39: 387, 1998
19. 19. Liao DJ, Pantazis CG, Hou X, Li SA: Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: Probable mediation by steroid receptor. Carcinogenesis 19: 2173-2180, 1998
20. 20. Wakefield LM, Smith DM, Masui T, Harris CC, Sporn MB: Distribution and modulation of the cellular receptor for transforming growth factor β. J Cell Biol 105: 965-975, 1987
21. 21. Gregoire M, Lieubeau B: The role of fibroblasts in tumor behavior. Cancer Metast Rev 14: 339-350, 1995
22. 22. Manning AM, Williams AC, Game SM, Paraskeva C: Differential sensitivity of human colonic adenoma and conversion of andenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGFβ. Oncogene 6: 1471-1476, 1991
23. 23. Brattain MG, Markowitz SD, Willson JKV: The type II transforming growth factor-β receptor as a tumor suppressor gene. Current Opinion in Oncology 8: 49-53, 1996
24. 24. Vincent F, Hagiwara K, Ke Y, Stoner GD, Demetrick DJ, Bennett WP: Mutation analysis of transforming growth factor P type II receptor in sporadic human cancers of the pancreas, liver, and breast. Biochem Biophy Res Commun 223: 561-564, 1996
25. 25. Jakowlew SB, Moody TW, Mariano JM: Transforming growth factor-beta receptors in human cancer cell lines: Analysis of transcript, protein and proliferation. Anticancer Res 17: 1849-1860, 1997
26. 26. Rudland PS, Fernig DG, Smith JA: Growth factors and their receptors in neoplastic mammary glands. Biomed Pharmacother 49: 389-399, 1995
27. 27. Panico L, D'Antonio A, Salvatore G, Mezza E, Tortora G, De Laurentiis M, De Placido S, Giordano T, Meino M, Salomon DS, Gullick WJ, Pettinato G, Schnitt SJ, Bianco AR, Ciardiello F: Differential immunohistochemical detection of transforming growth factor α, amphiregulin and cripto in human normal and malignant breast tissues. Int J Cancer 65: 51-56, 1996
28. 28. Bates SE, Davidson N, Valverius EM, Freter C, Dickson RB, Tam J, Kudlow J, Lippman ME, Salomon DS: Expression of transforming growth factor α and its messenger ribonucleic acid in human breast cancer its regulation by estrogen and its possible functional significance. Mol Endocrinol 2: 543-555, 1988
29. 29. Auvinen PK, Lipponen PK, Kataja VV, Johansson RT, Syrjanen KJ: Prognostic significance of TGF-alpha expression in breast cancer. Acta Oncol 35: 995-998, 1996
30. 30. Levenson AS, Tonetti DA, Jordan VC: The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 77: 1812-1819, 1998
31. 31. Klijin JG, Berns PM, Schmitz, PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 13: 3-9, 1992
32. 32. Sneder SM, Diaugustine RP: Hormonal and environmental factors affecting cell proliferation and neoplasia in the mammary gland. Prog Clin Biol Res 394: 211-253, 1996
33. 33. Lee CSL, Koga M, Sutherland RL: Modulation of estrogen-receptor and epidermal growth factor receptor messenger-RNAs by phorbol ester in MCF-7 breast cancer cells. Biochem Biophys Res Commun 162: 415-426, 1989
34. 34. Bucci B, D'Agnano I, Botti C, Mottolese M, Carico E, Zupi G, Vecchione A: EGF-R expression in ductal breast cancer: Proliferation and prognostic implications. Anticancer Res 17: 769-774, 1997
35. 35. Rosen PP: Rosen's breast pathology. Lippincott Raven, New York, 1997
36. 36. Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB: Transforming growth factor-β: Possible roles in carcinogenesis. Br J Cancer 57: 594-600, 1988
37. 37. Roberts AB, Sporn MB: Transforming growth factor β. Adv Cancer Res 51: 107-145, 1988
38. 38. Zajchowoski D, Band V, Pauzid N, Iager A, Stampfer M, Sager R: Expression of growth factors and oncogenes in normal and tumor-derived human mammary epithelial cells. Cancer Res 48: 7041-7047, 1988
39. 39. Valverius EM, Walker-Jones D, Bates SE, Stampfer MR, Mccormick F, Dickson RB, Lippman ME: Production of and responsiveness to transforming growth factor-beta in normal and oncogene-transformed human mammary epithelial cells. Cancer Res 49: 6269-6274, 1989
40. 40. Hong WK, Lippman ME, Itri LM, Karp DD, Leer JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ: Prevention of second primary tumors with isoretinoids in squamous cell carcinoma of the head and neck. N Engl J Med 323: 795-801, 1990
41. 41. Airteaga CL, Dugger TC, Hurd SD: The multifunctional of transforming growth factor (TGF)-beta on mammary epithelial cell biology. Breast Cancer Res Treat 38: 49-56, 1996
42. 42. King RJ, Wang DY, Daly RJ, Darbre PD: Approaches to studying the role of growth factors in progression of breast tumors from the steroid sensitive to insensitive state. J Steroid Biochem, 34: 133-138, 1989
43. 43. Daly RJ, King RJB, Darbre PD: Interaction of growth factors during the progression towards steroid independence in T-47-D human breast cancer cells. J Cell Biochem 43: 199-211, 1990
44. 44. Welch DR, Fabra A, Nakajima M: Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metaslatic potential. Proc Natl Acad Sci USA 87: 7678-7682, 1990
45. 45. Norgaard F, Hougaard S, Poulsen HS, Spang-Thomsen M: Transforming growth factor β and cancer. Cancer Treat Rev 21: 367-403, 1995
46. 46. Azuma M, Yuki T, Tamatani T, Motegi K, Yoshida H, Sato M: Lake of expression of 44 transforming growth factor-β type II receptor associated with malignant progression in human salivary gland cell clones. Int J Cancer 66: 802-805, 1996
47. 47. Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K, Bang Y-J, Lee HY, Park I-G, Lynch HT, Roberts AB, Vogelstein B, Markowitz SD: A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instablity. Cancer Res 55: 5545-5547, 1995
48. 48. Munoz-Antonia T, Li X, Reiss M, Jackson R, Antonia SA: Mutation in the transforming growth factor β type II receptor gene promoter associated with loss of gene expression. Cancer Res 56: 4831-4835, 1996
49. 49. Derynck R, Zhang Y: Intracellular signaling: the Mad way to do it. Curr Biol 6: 1226-1229, 1996
50. 50. Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana IL: MADR2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 87: 1215-1224, 1996
51. 51. Chen Y, Lebrun JJ, Vale W: Regulation of transforming growth factor β and activin induced transcription by mammalian Mad protein. Proc Natl Acad Sci USA 93: 12992-12997, 1996
52. 52. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J: Partnership between DPC4 and SMAD proteins in TGF-β signaling pathways. Nature 383: 832-836, 1996
53. 53. De Winter JP, Roelen BA, ten Dijke P, van der Burg B, van den Eijnden-van Raaij AJ: DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumor cells. Oncogene 14: 1891-1899, 1997
54. 54. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M: Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 389: 85-89, 1997
55. 55. Garrigue-Antar L, Munzo-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF, Reiss M: Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Res 55: 3982-3987, 1995
56. 56. Takenoshita S, Tani M, Nagashima M, Hagiwara K, Bennett WP, Yokota J, Harris CC: Mutation analysis of coding sequences of the entire transforming growth factor β type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene 14: 1255-1258, 1997
57. 57. Langdon SP, Miller WR: Introduction to the cell and molecular biology of cancer. In: Langdon SF, Miller WR, Berchuck A (eds) Biology of female cancers. CRC press New York, 1997, pp 3-28
58. 58. DiGiovanni J: Multistage carcinogenesis in mouse skin. Pharmac Ther 54: 63-128, 1992
59. 59. Wakefield LM, Letterio JJ, Geiser AG, Flander KC, O'Shaugnessy J, Roberts AB, Sporn MB: Transforming growth factor-βs in mammary tumorigenesis: Promoters or antipromoters? In: McClain RM, Slaga TJ, LeBoeuf R, Pitot H (eds) Growth factors and tumor promotion. Wiley-Liss Press, New York, 1995, pp 133-148
60. 60. Artagaveytia N, Le-Penven S, Falette N, Lucero R, Garofalo EG, Saez S: Epidermal growth factor and transforming growth factor alpha mRNA expression in human breast cancer biopsies; analysis in relation to estradiol, progesterone and EGF receptor content. J Steroid Biochem Mol Biol 60: 221-228, 1997
61. 61. Schroeder W, Biesterfeld S, Zillessen S, Rath W: Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 17: 2799-2802, 1997
62. 62. Lee CS, deFazio A, Ormandy CJ, Sutherland RL: Inverse regulation of oestrogen receptor and epidermal growth factor receptor gene expression in MCF-7 breast cancer cells treated with phorbol ester. J Steroid Biochem Mol Biol 58: 267-275, 1996
63. 63. Xie B, Tsao SW, Wong YC: Sex hormone-induced mammary carcinogenesis in female Noble rats: the rate of androgens. Carcinogenesis 20: 1597-1606, 1999